Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.

[1]  D. Fabbro,et al.  PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. , 2006, Blood.

[2]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. , 2005, Biochimica et biophysica acta.

[3]  K. Bhalla,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL). , 2005 .

[4]  C. Chen,et al.  Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. , 2005, Blood.

[5]  Z. Estrov,et al.  AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.

[6]  F. Lordick,et al.  The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 , 2005, Leukemia.

[7]  B. Druker,et al.  In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. , 2005, Blood.

[8]  J. Mestan,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia , 2005, Clinical Cancer Research.

[9]  R. Hehlmann,et al.  Chronic myeloid leukemia: a model for oncology , 2005, Annals of Hematology.

[10]  A. Pardanani.  Systemic Mastocytosis: Bone Marrow Pathology, Classification, and Current Therapies , 2005, Acta Haematologica.

[11]  J. Butterfield.  Interferon Treatment for Hypereosinophilic Syndromes and Systemic Mastocytosis , 2005, Acta Haematologica.

[12]  A. Itai,et al.  A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. , 2005, Blood.

[13]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[14]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[15]  B. Druker,et al.  Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. , 2004, Blood.

[16]  M. Heinrich,et al.  BMS-354825 Potently Inhibits the Kinase Activity of KIT Activation Loop Mutations Associated with Systemic Mastocytosis and Induces Apoptosis of Mastocytosis Cell Lines. , 2004 .

[17]  D. Metcalfe,et al.  The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.

[18]  L. Neckers,et al.  17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. , 2004, Blood.

[19]  H. Kluin-Nelemans,et al.  Cladribine therapy for systemic mastocytosis. , 2003, Blood.

[20]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.